文献速递泌尿生殖介入CTPET

前列腺癌主动脉旁寡复发立体定向体部放疗后的复发模式:多中心分析

Pattern of recurrence after stereotactic body radiotherapy for para-aortic oligo-recurrent prostate cancer, a multicentric analysis.
PubMed 文献 · Radiol Med · 2023-08-19

该多中心分析基于前瞻性收集的数据,纳入两所机构中经根治性放疗或根治性前列腺切除术后出现主动脉旁寡复发M1a病变(≤3个淋巴结,位于主动脉分叉以上、肾动脉以下)的患者,所有复发灶均接受SBRT。中位无进展生存期为10个月(95% CI 8–17),中位总生存期为114个月(95% CI 85–114),83例复发中43.37%为主动脉旁复发,18%为远处复发,22.9%为生化复发伴再分期影像阴性。作者认为MDT在CSPC和CRPC混合队列中提供了显著的PFS结局和良好的安全性,并指出需要前瞻性试验比较MDT与ENRT。

要点

  • 主动脉旁寡复发定义为≤3个淋巴结,位于主动脉分叉以上、肾动脉以下。
  • SBRT后中位PFS为10个月(95% CI 8–17),中位OS为114个月(95% CI 85–114)。
  • 83例复发中主动脉旁复发占43.37%,远处复发占18%,生化复发伴影像阴性占22.9%。

核心结论

  • MDT在CSPC和CRPC混合的M1a患者中提供了显著的PFS结局和良好的安全性,但需要前瞻性试验比较MDT与ENRT以选择最佳治疗方案。

研究设计与样本

  • 多中心分析,数据来自两所机构前瞻性收集的数据集,纳入根治性放疗或根治性前列腺切除术后寡复发M1a病变(≤3个淋巴结,位于主动脉分叉以上、肾动脉以下)患者,包括CRPC和CSPC,允许CT、胆碱PET/CT或PSMA PET/CT检测复发,所有复发灶接受SBRT。

局限性

  • 需要前瞻性试验比较MDT与ENRT,以选择最佳治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: M1a disease represents an intermediate status between loco-regional relapse and bone metastatic disease. Metastasis directed therapy (MDT), through stereotactic body RT (SBRT) may be offered to patients, aiming to exclusively treat sites of macroscopic relapse and avoiding wide prophylactic treatment volumes. This appears as a viable treatment, especially after the rise of PSMA tailored treatment approaches.

MATERIALS AND METHODS: Data about patients treated in two different institutions were retrieved from a prospectively collected dataset. All included patients were affected by oligo-recurrent M1a disease after definitive RT or radical prostatectomy, defined as ≤ 3 nodal lesions situated above aortic bifurcation and below renal arteries. Both castration resistant PCa (CRPC) and castration sensitive (CSPC) PCa patients were included. All imaging methods were allowed to detect recurrence (CT scan, Choline or PSMA PET/CT).All sites of recurrences were treated with SBRT.

RESULTS: Median PFS was 10 months (95% CI 8-17). Twelve patients died, with a median OS of 114 months (95% CI 85-114). Out of the 83 recurrences, 2 (2.4%), 11 (13.25%), 36 (43.37%) and 15 (18%) patients had respectively prostate bed only, pelvic nodal, para-aortic or distant relapse. Furthermore, 19 (22.9%) patients experienced a biochemical only relapse with negative imaging at re-staging.

DISCUSSION: MDT conferred a remarkable PFS outcome in a mixed cohort of CSPC and CRPC patients with m1a disease, with an optimal safety profile. Prospective trials are needed in order to compare MDT and ENRT for these patients, allowing to select the best treatment option.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Francolini G, Garlatti P, Di Cataldo V, et al. Pattern of recurrence after stereotactic body radiotherapy for para-aortic oligo-recurrent prostate cancer, a multicentric analysis. Radiol Med. 2023. PMID: 37597125. doi:10.1007/s11547-023-01701-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。